North America Intravenous Immunoglobulin Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Intravenous Immunoglobulin Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Intravenous Immunoglobulin Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Intravenous Immunoglobulin Market Regional Analysis

6.2 North America Intravenous Immunoglobulin Market Revenue 2020-2030 (US$ Million)

6.3 North America Intravenous Immunoglobulin Market Forecast Analysis

7. North America Intravenous Immunoglobulin Market Analysis – by Type

7.1 IgG

7.1.1 Overview
7.1.2 IgG: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 IgA

7.2.1 Overview
7.2.2 IgA: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 IgM

7.3.1 Overview
7.3.2 IgM: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. North America Intravenous Immunoglobulin Market Analysis – by Application

8.1 Immunodeficiency Diseases

8.1.1 Overview
8.1.2 Immunodeficiency Diseases: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Chronic Inflammatory Demyelinating Polyneuropathy

8.2.1 Overview
8.2.2 Chronic Inflammatory Demyelinating Polyneuropathy: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.3 Idiopathic Thrombocytopenic Purpura

8.3.1 Overview
8.3.2 Idiopathic Thrombocytopenic Purpura: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.4 Multifocal Motor Neuropathy

8.4.1 Overview
8.4.2 Multifocal Motor Neuropathy: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.5 Hypogammaglobulinemia

8.5.1 Overview
8.5.2 Hypogammaglobulinemia: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.6 Guillain-Barre Syndrome

8.6.1 Overview
8.6.2 Guillain-Barre Syndrome: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.7 Specific Antibody Deficiency

8.7.1 Overview
8.7.2 Specific Antibody Deficiency: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.8 Inflammatory Myopathies

8.8.1 Overview
8.8.2 Inflammatory Myopathies: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.9 Myasthenia Gravis

8.9.1 Overview
8.9.2 Myasthenia Gravis: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. North America Intravenous Immunoglobulin Market Analysis – by Distribution Channel

9.1 Hospital Pharmacy

9.1.1 Overview
9.1.2 Hospital Pharmacy: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.2 Retail Pharmacy

9.2.1 Overview
9.2.2 Retail Pharmacy: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. North America Intravenous Immunoglobulin Market Analysis – by End User

10.1 Hospitals

10.1.1 Overview
10.1.2 Hospitals: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

10.2 Specialty Clinics

10.2.1 Overview
10.2.2 Specialty Clinics: North America Intravenous Immunoglobulin Market – Revenue and Forecast, 2020-2030 (US$ Million)

11. North America Intravenous Immunoglobulin Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America Intravenous Immunoglobulin Market Breakdown, by Key Country, 2023 and 2030 (%)
11.2.1.1 North America Intravenous Immunoglobulin Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.1.1 US: North America Intravenous Immunoglobulin Market Breakdown, by Type
11.2.1.1.2 US: North America Intravenous Immunoglobulin Market Breakdown, by Application
11.2.1.1.3 US: North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel
11.2.1.1.4 US: North America Intravenous Immunoglobulin Market Breakdown, by End User

11.2.1.2 Canada: North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.2.1 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Type
11.2.1.2.2 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Application
11.2.1.2.3 Canada: North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel
11.2.1.2.4 Canada: North America Intravenous Immunoglobulin Market Breakdown, by End User

11.2.1.3 Mexico : North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.3.1 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Type
11.2.1.3.2 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Application
11.2.1.3.3 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by Distribution Channel
11.2.1.3.4 Mexico : North America Intravenous Immunoglobulin Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Takeda Pharmaceutical Co Ltd

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Grifols SA

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Pfizer Inc

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 ADMA Biologics, Inc

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Bio Products Laboratory Ltd

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Octapharma AG

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Kedrion SpA

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 CSL Ltd

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 LFB Group

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Prothya Biosolutions B.V

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America Intravenous Immunoglobulin Market